Lyell Immunopharma develops next-generation CAR T-cell therapies intended to produce durable remissions in patients with hematologic malignancies and solid tumors. The clinical-stage company applies proprietary technologies to engineer T cells with enhanced persistence, resistance to exhaustion, and stem-like qualities suited to the tumor microenvironment. It maintains integrated capabilities in discovery, manufacturing, and clinical development to advance its pipeline of cell therapy product candidates.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -42.7 | — |
| Q3 2025 | 0 | — | -38.9 | — |
| Q4 2025 | 0 | — | -140.7 | — |
| Q1 2026 | 0 | — | -24.1 | — |
| Q2 2026 | 0 | -50% | -44.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Clean Energy Fuels Corp. (CLNE), Axiom Intelligence Acquisition Corp 1 (AXIN), BlackRock TCP Capital Corp. (TCPC), Value Line, Inc. (VALU), HCM III Acquisition Corp. (HCMA), Arqit Quantum Inc. (ARQQ)